Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
Sign in
Join now
Colin Howden MD

Colin W. Howden MD

Emeritus Professor of Medicine, University of Tennessee College of Medicine, Memphis, Tennessee

Disclosures

Dr. Howden is a consultant for Ironwood Pharmaceuticals, RedHill Biopharma, and Phathom Pharmaceuticals and owns stock in Antibe Therapeutics.

There was no financial support for writing this brief commentary.

Recent Contributions to PracticeUpdate:

  1. Association of Helicobacter pylori Treatment With the Risk of Gastric Cancer After Endoscopic Resection of Dysplasia
  2. Physicians' Perceptions of PPI Risks and Recommendations to Discontinue

Most Read This Week

Recently Updated